Skip to main content
  • COVID-19
    • COVID-19 vaccines and cancer
      • FAQs
      • FAQs in-language
      • SerOzNET Study
    • COVID-19 information for people affected by cancer
      • Managing your cancer care in the context of COVID-19
      • Looking after your mental wellbeing
      • Canada
      • Ireland
      • UK
      • USA
    • COVID-19 information for children and young people with cancer
    • Cancer Won’t Wait
    • Cancer and COVID-19 - what it means for our Mob
      • COVID-19 vaccines: Information for Aboriginal and Torres Strait Islander people affected by cancer
      • Act early for our Mob's health
    • Guidance for health professionals
      • Diagnosis
      • Treatment
      • Surgery
      • Medical oncology
      • Radiation oncology
      • Primary care
      • Telehealth
      • Clinical trials
      • Follow-up care
      • Supportive and Palliative care
      • Cancer care for cancer patients with COVID-19
      • COVID-19 vaccines and cancer
      • Recovery
    • Research articles
      • Review articles
      • Data articles
      • Recommendations articles
      • Shared experience articles
      • COVID-19 vaccines and cancer articles
    • Cancer care in the time of COVID-19: A conceptual framework
    • Optimal cancer care during the COVID-19 pandemic: the Principles
    • The impact of COVID-19 on cancer services
    • COVID-19 Recovery: Implications for cancer care
      • Expanded use of telehealth
      • Changes to prevention and early detection
      • Virtual multidisciplinary team meetings
      • Modifications to treatment schedules
      • Hypofractionated radiotherapy
      • Oncology hospital in the home
      • Responsive patient support
      • Innovative care and hospital infrastructure models
      • Shared follow-up and survivorship care
      • Supportive and palliative care
      • Cancer research and clinical trials
      • Collaboration in the oncology sector and data sharing
      • Acknowledgements
  • About us
    • Organisational structure
    • Accountability and reporting
      • Annual reports
    • Who we work with
      • Roles & functions
      • Advisory Council
      • Advisory groups
      • Consumer engagement
      • Government cancer control organisations
    • Information publication scheme
      • Information publication scheme plan
      • Freedom of information act
        • The FOI request process
      • FOI disclosure log
    • Reconciliation action plan
    • Employment opportunities
  • News and media
    • News
    • Subscribe to our eNewsletter
  • Contact us
Cancer Australia
Choose Language
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • العربية
  • 简体中文
  • 繁體中文
  • Ελληνικά
  • हिन्दी
  • Italiano
  • 한국어
  • Español
  • Tagalog
  • Tiếng Việt
  • Home
  • Cancer types
  • Impacted by Cancer
  • Awareness
  • Research
  • Resources
  • Clinicians hub
  • Key initiatives
  • Home
  • Cancer types
    • Bladder cancer
    • Bowel cancer
    • Brain cancer
    • Breast cancer
    • Breast cancer in men
    • Breast cancer in young women
    • Cervical cancer
    • Children’s cancer
    • Endometrial cancer
    • Fallopian cancer
    • Gestational trophoblastic disease
    • Gynaecological cancers
    • Head and neck cancer
    • Kidney cancer
    • Leukaemia
    • Liver cancer
    • Lung cancer
    • Lymphoma
    • Melanoma
    • Mesothelioma cancer
    • Myeloma
    • Neuroendocrine tumours
    • Oesophageal cancer
    • Ovarian cancer
    • Pancreatic cancer
    • Prostate cancer
    • Sarcoma
    • Stomach cancer
    • Testicular cancer
    • Thyroid cancer
    • Unknown primary cancer
    • Uterine sarcoma
    • Vaginal cancer
    • Vulvar cancer
  • Impacted by Cancer
    • What is cancer
    • Physical changes
    • Treatment
    • Keeping healthy
    • Emotions
    • Family and relationships
    • Living with cancer
    • Lynch Syndrome
  • Awareness
    • Your cancer risk
    • Screening
    • Interactive body map
  • Research
    • Cancer Research in Australia
    • Data and statistics
    • Australian Clinical Trials
    • Support for cancer clinical trials
    • Grants and funding
  • Resources
    • Cancer Australia Publications
    • Clinical Practice Guidelines
    • Position statements
    • Resources in other languages
    • Cancer Australia websites
    • Cancer risk online assessment tools
    • Other tools and resources
    • Podcasts
    • Cancer support organisations
    • Glossary
  • Clinicians hub
    • GP guides and resources
    • Guidelines by cancer type
    • Optimal Care pathways
    • Working with Aboriginal and Torres Strait Islander people
    • Multidisciplinary care
    • Psychosocial care
    • Follow-up care
    • Family cancer clinics
    • Cancer Learning
    • Consumer engagement
  • Key initiatives
    • For Aboriginal and Torres Strait Islander people
    • Australian Cancer Plan
    • Australian Brain Cancer Mission
    • Lung Cancer Screening
    • National Pancreatic Cancer Roadmap
    • Campaigns & events
    • Jeannie Ferris Recognition Award

Lymphoma

lymphoma-mm cancer-types/lymphoma/overview
    • Home
    • Types
    • Statistics
    • Risk factors
    • Symptoms
    • Diagnosis
    • Treatment
    • Finding support
    • Clinical trials
    • Health professionals
    • Home
    • Types
    • Statistics
    • Risk factors
    • Symptoms
    • Diagnosis
    • Treatment
    • Finding support
    • Clinical trials
    • Health professionals
  1. Home
  2. Statistics
Loading...

Lymphoma in Australia statistics

  • Printer-friendly version
  • A|A

The following material has been sourced from the Australian Institute of Health and Welfare

Lymphoma incorporates ICD-10 cancer codes C81 (Hodgkin’s disease), C82 (follicular non-Hodgkin’s lymphoma), C83 (diffuse non-Hodgkin’s lymphoma), C84 (peripheral and cutaneous T-cell lymphomas) and C85 (other and unspecified types of non-Hodgkin’s lymphoma). 


Estimated number of new cases of lymphoma diagnosed in 2022

7,397 = Male icon PNG 4,267 males + Female icon PNG 3,130 females


Estimated % of all new cancer cases diagnosed in 2022

4.6%


Estimated number of deaths from lymphoma in 2022

1,766 = Male icon PNG 1,017 males + Female icon PNG 749 females


Estimated % of all deaths from cancer in 2022

3.5%


Chance of surviving at least 5 years (2014–2018)

78%


People living with lymphoma at the end of 2017 (diagnosed in the 5 year period 2013 to 2017)

23,141


New cases

In 2018, non-Hodgkin lymphoma was the sixth most commonly diagnosed cancer in Australia. It is estimated that it will remain the sixth most commonly diagnosed cancer in 2022. Non-Hodgkin lymphoma makes up approximately 90% of lymphoma cases in Australia.

In 2018, there were 6,438 new cases of lymphoma diagnosed in Australia (3,735 males and 2,702 females). In 2022, it is estimated that 7,397 new cases of lymphoma will be diagnosed in Australia (4,267 males and 3,130 females). In 2022, it is estimated that a person has a 1 in 40 (or 2.5%) risk of being diagnosed with lymphoma by the age of 85 (1 in 35 or 2.9% for males and 1 in 48 or 2.1% for females).

Figure 1. Estimated cancer incidence in Australia, 2022

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about incidence rates for the most common cancers diagnosed can be found on the NCCI website in the ‘Cancer incidence’ section (https://ncci.canceraustralia.gov.au/diagnosis/cancer-incidence/cancer-incidence) 

In 2018, the age-standardised incidence rate was 22 cases per 100,000 persons (27 for males and 18 for females). In 2022, it is estimated that the age-standardised incidence rate will be 23 cases per 100,000 persons (28 for males and 19 for females). The incidence rate for lymphoma is expected to increase with age, highest for those aged 80–84 years.

Figure 2. Age-standardised incidence rates for lymphoma, 1982 to 2018, by sex

Notes: 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about incidence rates for the most common cancers diagnosed can be found on the NCCI website in the ‘Cancer incidence’ section (https://ncci.canceraustralia.gov.au/diagnosis/cancer-incidence/cancer-incidence) 

The number of new cases of lymphoma diagnosed increased from 1,745 (937 males and 808 females) in 1982 to 6,438 in 2018. Over the same period, the age-standardised incidence rate increased from 14 cases per 100,000 persons (16 for males and 12 for females) in 1982 to 22 cases per 100,000 in 2018.

Deaths 

In 2020, non-Hodgkin lymphoma was the eighth most common cause of cancer death in Australia. It is estimated that it will remain the eighth most common cause of death from cancer in 2022.

In 2020, there were 1,679 deaths from lymphoma in Australia (961 males and 718 females). In 2022, it is estimated that there will be 1,766 deaths (1,017 males and 749 females). In 2022, it is estimated that a person has a 1 in 185 (or 0.54%) risk of dying from lymphoma by the age of 85 (1 in 157 or 0.64% for males and 1 in 227 or 0.44% for females).

 

Figure 3. Estimated cancer mortality in Australia, 2022

Notes 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about mortality rates for the most common causes of cancer death can be found on the NCCI website in the ‘Cancer mortality’ section (https://ncci.canceraustralia.gov.au/outcomes/cancer-mortality/cancer-mortality)

In 2020, the age-standardised mortality rate was 5.2 deaths per 100,000 persons (6.5 for males and 4.0 for females). In 2022, it is estimated that the age-standardised mortality rate will be 5.1 deaths per 100,000 persons (6.4 for males and 3.9 for females). The mortality rate for lymphoma is expected to increase with age.

Mortality rates for lymphoma

Figure 4. Age-standardised mortality rates for lymphoma, 1982 to 2020, by sex

Notes: 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about mortality rates for lymphoma over time, by age, sex, Indigenous status, remoteness, and socioeconomic status (SES) can be found on the NCCI website in the ‘Cancer mortality’ section (https://ncci.canceraustralia.gov.au/outcomes/cancer-mortality/cancer-mortality)

The number of deaths from lymphoma increased from 918 (509 males and 409 females) in 1982 to 1,679 in 2020. Over the same period, the age-standardised mortality rate remained similar from 7.4 deaths per 100,000 persons (9.1 for males and 6.0 for females) in 1982 to 5.2 deaths per 100,000 in 2020. 

Survival 

In 2014–2018, individuals diagnosed with lymphoma had a 78% chance (76% for males and 79% for females) of surviving for five years compared to their counterparts in the general Australian population. Between 1989–1993 and 2014–2018, five-year relative survival for lymphoma improved from 54% to 78%. 

Figure 5. 5-year relative survival for lymphoma, 1989–1993 to 2014–2018, by sex

Notes: 

  • Data sourced from AIHW Cancer Data in Australia 2022 web report and supplementary data tables
  • More information about 5-year relative survival rates for lymphoma over time, by age, sex, Indigenous status, remoteness, and socioeconomic status (SES) can be found on the NCCI website in the ‘Relative survival rate’ section (https://ncci.canceraustralia.gov.au/outcomes/relative-survival-rate/5-year-relative-survival)

Prevalence 

At the end of 2017, there were 5,702 people living who had been diagnosed with lymphoma that year, 23,141 people living who had been diagnosed with lymphoma in the previous 5 years (from 2013 to 2017) and 62,378 people living who had been diagnosed with lymphoma in the previous 36 years (from 1982 to 2017).

For more information, see Lymphoma on the NCCI website

The National Cancer Control Indicators (NCCI) are a set of indicators across the continuum of cancer care, from Prevention and Screening through to Diagnosis, Treatment, Psychosocial care, Research and Outcomes.  The NCCI website allows users to see visual representations of data on each indicator through interactive charts.

  • Last Updated
  • Relevant Links
updated: 15 September 2022 - 10:03am
Lymphoma Australia
Cancer Council Australia
Leukaemia Foundation Australia
Lymphoma care pathway (Aus)
Cancer Australia Children’s Cancer
National Cancer Institute
American Cancer Society

Related information

What is cancer?
What is cancer?

Cancer is a disease of the cells, which are the body’s basic building blocks.

Treatment and side effects
Treatment and side effects

The treatment that your doctors recommend will depend on the type of cancer you have, how advanced it is, and other personal factors.

Living with cancer
Living with cancer

A diagnosis of cancer marks the beginning of a journey full of emotional, psychological, physical and practical challenges.

Life after cancer
Life after cancer

While looking forward to finishing their cancer treatment and getting on with life, for some people, the end of treatment can also be a confusing or worrying time.

A-Z List of Cancer Types

Information on more than 70 types of cancer

  • Bladder cancer
  • Bowel cancer
  • Brain cancer
  • Breast cancer
  • Breast cancer in men
  • Breast cancer in young women
  • Cervical cancer
  • Children's Cancer
  • Endometrial cancer
  • Fallopian cancer
  • Gestational trophoblastic disease
  • Gynaecological cancers
  • Head and neck cancer
  • Kidney cancer
  • Leukaemia
  • Liver cancer
  • Lung cancer
  • Lymphoma
  • Melanoma of the skin
  • Mesothelioma cancer
  • Myeloma
  • Neuroendocrine tumours
  • Oesophageal cancer
  • Ovarian cancer
  • Pancreatic cancer
  • Prostate cancer
  • Sarcoma
  • Stomach cancer
  • Testicular cancer
  • Thyroid cancer
  • Unknown primary
  • Uterine sarcoma
  • Vaginal cancer
  • Vulval cancer

About Cancer Australia

Cancer Australia was established by the Australian Government in 2006 to benefit all Australians affected by cancer, and their families and carers. Cancer Australia aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer by leading and coordinating national, evidence-based interventions across the continuum of care.

If you would like an interpreter to help you understand any information on this website, please call TIS National on 131 450 and ask them to call Cancer Australia on 02 9357 9400. Our business hours are 9am to 5pm, Monday to Friday.

Freecall 1800 624 973
+61 2 9357 9400

Locked Bag 3, Strawberry Hills
NSW 2012

Navigation

  • Cancer types
  • Impacted by Cancer
  • Awareness
  • Research
  • Resources
  • Clinicians hub
  • Key initiatives

Contact us

* Denotes mandatory fields
 

By submitting this form, you accept the Cancer Australia privacy policy.

  • Contact Us
  • Copyright
  • Disclaimer
  • Privacy policy
  • Sitemap
Copyright © 2023 - Cancer Australia